Charles River Laboratories International, Inc. (CRL) fair value analysis

S&P 500 · Updated 2026-09-07

Charles River Laboratories International, Inc. provides drug discovery, development, and safety testing services for the pharmaceutical, biotechnology, and chemical industries. The company operates laboratories and facilities across North America, Europe, and Asia to support its clients' research and regulatory requirements.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, CRL is trading at a 10–25% premium to estimated fair value.

CRL currently ranks #99 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $288.50
Sector: Healthcare
12-month range: $165.78–$282.34

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Contracting
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for CRL

Our model validated 17 trailing price-to-earnings windows for CRL, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $165.78–$282.34.
The 14-day relative strength index sits at a neutral 61.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for CRL
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent CRL news

TickrTrends' derived news-sentiment signal for CRL is currently leaning positive, computed from recent coverage.

Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors (gurufocus.com, 2026-09-02)
TickrTrends take: Charles River Laboratories International Inc (CRL) experienced a recent share price increase, though this movement occurs within a valuation context where TickrTrends currently assesses the stock as overvalued. The GF Score of 70 indicates a moderately strong fundamental quality rating, which investors focused on valuation should weigh against the current overvalued assessment to determine their risk-reward positioning. Given CRL's Healthcare sector classification and the divergence between fundamental quality and valuation status, investors may need to monitor whether the company's performance justifies its current market price or if valuation compression could occur.
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock? (finance.yahoo.com, 2026-08-26)
TickrTrends take: Charles River Laboratories operates in the Healthcare sector and is currently assessed as Overvalued by TickrTrends valuation metrics. Market sentiment analysis regarding CRL would be particularly relevant for investors monitoring whether Wall Street's positioning aligns with or diverges from current valuation assessments. Readers focused on valuation should track whether analyst sentiment shifts or if market conditions narrow the gap between current pricing and fundamental value indicators.
Charles River Posts Loss In Q2; Increases 2026 Guidance For Revenue, Non-GAAP EPS (rttnews.com, 2026-08-05)
TickrTrends take: Charles River Laboratories reported a loss in the second quarter while simultaneously raising its full-year 2026 guidance for both revenue and non-GAAP earnings per share. This combination of near-term losses alongside increased forward guidance suggests management confidence in future profitability, though TickrTrends currently assesses the stock as overvalued within the Healthcare sector. Investors focused on valuation should monitor whether the company can translate its optimistic 2026 outlook into actual earnings growth that would justify the current stock price.

What people are saying

Follow the CRL conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for CRL showed a shift this week as the Relative Strength Index moved from overbought territory into neutral zone, suggesting a moderation in the stock's recent momentum. The stock maintains an overvalued valuation verdict within the healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is CRL stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), CRL is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is CRL's TickrTrends verdict?

CRL's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does CRL compare to other Healthcare stocks?

CRL ranks #99 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is CRL overbought or oversold?

CRL's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

CRL vs BMY · CRL vs CAH · CRL vs CNC · CRL vs DGX · CRL vs GILD